慢性乙型肝炎的RNA干扰疗法:进展,挑战和未来前景
Laura Sneller1, Christine Lin1, Angie Price1
1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
RNA干扰 (RNAi) 疗法在治疗慢性乙型肝炎 (CHB) 中表现有前途. 小干扰RNA (siRNA) 疗法正在开发中,以抑制乙型肝炎病毒 (HBV) 复制并减少病毒标记物.
科学领域:
- 肝病学和病毒免疫学
- 分子疗法和RNA生物学
背景情况:
- 慢性乙型肝炎 (CHB) 构成了全球健康的重大负担,许多患者需要终身治疗.
- 目前的治疗方法,主要是核类相似物,可以治疗但不能治愈CHB,这凸显了对新型治疗策略的需求.
研究的目的:
- 审查RNA干扰 (RNAi) 疗法的新兴潜力,用于治疗慢性乙型肝炎.
- 突出了针对乙型肝炎病毒 (HBV) 复制的基于RNAi的策略的最新进展.
主要方法:
- 探索RNA干扰机制,特别是小干扰RNA (siRNA),以准病毒RNA.
- 审查目前正在开发用于CHB治疗的RNAi治疗候选药物.
- 分析增强siRNA稳定性和输送的策略.
主要成果:
- RNAi疗法,特别是siRNA,显示出抑制HBV复制的潜力.
- 几种候选药物已在降低乙型肝炎表面抗原 (HBsAg) 水平方面表现出有效性.
- 一些研究报告治疗停止后持续的HBsAg损失,表明功能治愈的潜力.
结论:
- RNAi疗法代表了一个动态和有前途的前沿,用于开发有效的,持续治疗CHB.
- 对修改,传递载体和特定siRNA候选者的持续研究对于临床进展至关重要.
更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Retrovirus Life Cycles
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Experimental RNAi
